Journal
MARINE DRUGS
Volume 19, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/md19030149
Keywords
glycogen synthase kinase 3β inhibitor; structural-based optimization; diabetes; glucose uptake
Categories
Funding
- National Natural Science Foundation of China [22077018]
- Fudan University [JIH1615060]
Ask authors/readers for more resources
Meridianin C, a natural product derived from marine organisms, and its analogues B29 and B30 showed enhanced glucose uptake and GSK-3 beta inhibitory activities, indicating therapeutic potential for diabetes.
Glycogen synthase kinase 3 beta (GSK-3 beta) is a widely investigated molecular target for numerous diseases, and inhibition of GSK-3 beta activity has become an attractive approach for the treatment of diabetes. Meridianin C, an indole-based natural product isolated from marine Aplidium meridianum, has been reported as a potent GSK-3 beta inhibitor. In the present study, applying the structural-based optimization strategy, the pyrimidine group of meridianin C was modified by introducing different substituents based on the 2-aminopyrimidines-substituted pyrazolo pyridazine scaffold. Among them, compounds B29 and B30 showed a much higher glucose uptake than meridianin C (<5%) and the positive compound 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8, 16%), with no significant toxicity against HepG2 cells at the same time. Furthermore, they displayed good GSK-3 beta inhibitory activities (IC50 = 5.85; 24.4 mu M). These results suggest that these meridianin C analogues represent novel lead compounds with therapeutic potential for diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available